DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
Key Highlights
- ➤DataMEDS licenses U.S. DTC rights to REBOOT’s GLP-1 care platform
- ➤Health Lives Here will integrate GLP-1 management modules and monthly subscriptions
- ➤Revenue sharing covers subscriptions generated through the GLP Management Platform
- ➤REBOOT’s IP includes six patents and six pending applications
- ➤Data Health Partners is litigating with Teladoc over the licensed IP
Expert Statements
Paul Arena, Chief Executive Officer of REBOOT
“We believe REBOOT offers DataMEDS a competitive advantage in the GLP-1 patient management marketplace, offering solutions that will differentiate it from competitors and help Health Lives Here customers meet their goals while optimizing to minimize side effects through behavior and nutraceutical products.”
Paul Arena, Chief Executive Officer of REBOOT
“We believe that DataMEDS' partnership with NFL Alumni Health provides the marketing platform to attract customers to the Health Lives Here app.”
Paul Arena, Chief Executive Officer of REBOOT
“We also believe that DataMEDS integration of Tollo Health's suite of products focused on managing the weight care journey into the Health Lives Here offering provides it with a competitive advantage to retain customers.”
Gerald E. Commissiong, Interim Co-CEO of DataMEDS
“We are thrilled to have completed this agreement and now have access to this key intellectual property and weight care management platform that enables Health Lives Here to rapidly position itself in the emerging competition to acquire and retain consumers seeking to have successful outcomes while on GLP-1 medications.”
Gerald E. Commissiong, Interim Co-CEO of DataMEDS
“With this agreement now in place, we will begin the work to integrate REBOOT's technology into our Health Lives Here app so that we can begin to offer access to unique, subscription-based services to our customers that we expect will also drive revenue associated with pharmacy dispensing, nutraceutical sales, diagnostic lab testing and physician services as part of the Company's vertically integrated business model.”
Gerald E. Commissiong, Interim Co-CEO of DataMEDS
“We believe this will further differentiate the Health Lives Here ecosystem.”
TAMPA, FL / ACCESS Newswire / October 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has entered into an exclusive license, revenue sharing and marketing agreement with REBOOT Health AI, Inc. ("REBOOT") for Direct-to-Consumer (DTC) rights in the United States to REBOOT's proprietary care management platform. The Companies will work together to tailor the platform for use in the Health Lives Here mobile application for patients taking GLP-1 receptor agonist medications (the "GLP Management Platform") leveraging the patents and patent applications (the "IP") under the license. REBOOT is an operating subsidiary of Data Health Partners, Inc.
Get started
Create a free account to read the full story.